breast cancer

The study is the first large-scale clinical trial to show that a new oral endocrine therapy outperforms the long-standing standard therapies used for early-stage HR-positive/HER2-negative breast cancer.

Listen to Knaul, associate of the UCLA chancellor and a distinguished professor of medicine, on UCLA Health’s “Medically Speaking” podcast.

Here are just some of the lifesaving therapies that were developed by or stemmed from research at UCLA.

The clinical trial demonstrates that combining genetically engineered T cells and stem cells can produce cancer-fighting immune cells in humans.

The algorithm unlocks the full potential of proteogenomics by overcoming a key challenge in linking genetic mutations to protein-level changes.

A Harvard-trained health economist, Knaul has been engaged in public health research, social development and advocacy throughout her career.

Using artificial intelligence during routine screening could flag spots of concern invisible to the naked eye.

A team led by UCLA Health Jonsson Comprehensive Cancer Center doctors Dennis Slamon and Richard Finn, helped transform breast cancer treatment.

Chemotherapy can affect appetite and digestion, so preparation and flexibility are key.

Slamon’s innovations, including his work developing the breast cancer drug Herceptin, helped shape a new era in cancer therapy.

A therapeutic sponge the size of a pencil eraser boosted tumor-fighting responses in mice and kept cancer from returning.

UCLA researchers found that women’s reports of cognitive issues were related to higher levels of an inflammatory marker in the body called CRP.

A UCLA team recommends state-level policy changes to improve health insurance coverage, participation in clinical trials and access to palliative care.

Research brief: Chats on social media can serve as a timely source of data for policymakers aiming to enhance care and outcomes.

Since first appearing in 2011, #BCSM has been used on the social media platform more than 830,000 times.

The drug combination should be a first line of treatment, UCLA researchers say.

The prominent cancer researcher is honored for his invention of the breast cancer drug Herceptin.

The system could help reduce errors in differentiating ductal carcinoma in situ, a noninvasive type of cancer, from breast atypia.

“This trial was unique because it looks at younger women who haven’t gone through menopause,” said Dr. Sara Hurvitz, the study’s lead author.

The driving force behind the development of Herceptin will split a $1 million prize from the Royal Swedish Academy of Sciences and the Sjöberg Foundation.

The six-year-long study about endocrine treatment is contrary to expectations.

Researchers found that lower activity of an enzyme that helps maintain cells’ health along with DNA damage were associated with worse cognitive performance, such as attention and motor skills.

The findings may help to offer better solutions for preventing and managing fatigue.

UCLA participates in #PinkLA, in which buildings throughout the city are illuminated for Breast Cancer Awareness Month.

The next step is to determine why the numbers are so low and find ways to increase those rates of testing.